Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC
about
New β-Lactamase Inhibitors in the ClinicArt-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosaThe sentinel role of peptidoglycan recycling in the β-lactam resistance of the Gram-negative Enterobacteriaceae and Pseudomonas aeruginosa.The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.The problems of antibiotic resistance in cystic fibrosis and solutions.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.Improving outcomes in the management of Gram-negative bacterial infections in the face of growing antimicrobial resistance.Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Genomics and Susceptibility Profiles of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa from Spain.Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa.WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections.Persistent Bacteremia from Pseudomonas aeruginosa with In Vitro Resistance to the Novel Antibiotics Ceftolozane-Tazobactam and Ceftazidime-Avibactam.In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.Antibiotic-resistant ST38, ST131 and ST405 strains are the leading uropathogenic Escherichia coli clones in Riyadh, Saudi Arabia.Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.Emergence of Ceftolozane-Tazobactam Resistant Pseudomonas aeruginosa During Treatment is Mediated by a Single AmpC Structural Mutation.Dynamics of Mutations during Development of Resistance by Pseudomonas aeruginosa against Five Antibiotics.Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa.Diversity and regulation of intrinsic β-lactamases from non-fermenting and other Gram-negative opportunistic pathogens.Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.In Vitro Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for Pseudomonas aeruginosa.Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.Insights into the evolution of the mutational resistome of Pseudomonas aeruginosa in cystic fibrosis.Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa.Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
P2860
Q26747150-42B5A9BE-8255-4BBF-BB96-F0E0E941173CQ30581467-24DC0C56-5BBD-4A71-AB42-A0A82BE72B54Q34167642-A50907EF-8E0F-46D6-BB05-E11D5F25FA76Q35482558-BF6684F3-A451-4115-B28A-8C597DED26D9Q36075893-67820732-FC06-4502-88FA-ACA4E8225703Q38241417-06B32BDA-1D99-4B21-89C6-5851EA68C032Q38262205-1928245C-0528-4A16-A9B6-2095CD6BE92BQ38296151-4535E67B-6B63-4E6B-871B-1F609C352E30Q38300820-A5A5C52D-7C42-46AA-BABD-9E619120281CQ38690748-6274D038-85B8-4506-A82E-AF0E2392BF43Q38741337-44CBFBDC-00C6-4EF1-B790-2D9D83E3E19CQ38777049-6332C9EF-53AF-415C-97E0-E64C5B310C54Q38816907-22ED9CF4-BEDD-43E2-AD46-8361F1494897Q38844899-5CFBA847-6B35-4469-8382-52F1D1F6AF2FQ38934400-263CCA0C-3F70-422D-AAB7-7372DF66B3E6Q39120027-23DBA1EE-0E79-44DC-B4C4-C319658C7373Q40056971-97656BD6-8598-4776-9EBC-202A122F353FQ40095692-D4F0DAAB-D645-47A6-9364-BF07CE761FADQ40148490-246DFD55-C2FE-4CE9-8024-8485872122D7Q40296000-3FC2E557-979A-45C3-AE5A-ED9393563FA4Q40412684-8975F48A-24D0-47D8-A78F-EA846B874A91Q40461817-C4DD221C-16D8-42C8-933E-C24B6A18B2C1Q41060499-A331FC1D-7933-4F86-A090-FB4DA03E14CFQ41104461-27C57F99-970E-4E2F-8DA4-9989C6ECEB31Q41508049-E7A097F8-97F2-4F5A-8D22-E2474C499D68Q41757275-CA735A25-17B3-40AF-A8A1-91351782907FQ41994337-6FCFF5F4-E10D-4558-B71C-72C541E0A59CQ42089533-6B91DE07-756C-4146-A1E3-B8C482D294B3Q45897898-9032642B-4F7B-475B-AB5B-43027D51E465Q46286684-2117AA1E-60F4-4267-821D-23766CB3DCBAQ47218700-757EC3C9-6826-4137-9332-947EC2D862CAQ47396264-0EDE0C94-CB11-43D6-9E8B-6D7A648D7CD9Q47748447-77AFB123-39E5-44DE-897E-0723088EE735Q47769606-69B7432D-0665-4F82-9C3C-3028C1A0831DQ47822967-8CDA23A2-BB12-4471-B5FC-EB38DA0CB45BQ47877807-95940E87-4991-450B-88FA-B4570B90DD0DQ49445381-C910F89F-306A-4F79-9851-5C3947690998Q49616791-3330D991-8641-4956-A860-79A889A51EE6Q49921578-DB2B7161-64F4-44C3-873F-96DA36C2A0C1Q50221890-5D122B3B-AB4F-43B3-81E8-04DBE71D8EA9
P2860
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Pseudomonas aeruginosa ceftolo ...... tructural modification of AmpC
@en
type
label
Pseudomonas aeruginosa ceftolo ...... tructural modification of AmpC
@en
prefLabel
Pseudomonas aeruginosa ceftolo ...... tructural modification of AmpC
@en
P2093
P2860
P356
P1476
Pseudomonas aeruginosa ceftolo ...... tructural modification of AmpC
@en
P2093
Antonio Oliver
Bartolomé Moyà
Gabriel Cabot
Laura Zamorano
Susanne Haussler
Xavier Mulet
P2860
P304
P356
10.1128/AAC.02462-13
P407
P577
2014-03-17T00:00:00Z